Reticulate acropigmentation of Kitamura

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:178307OMIM:615537L81.8
Who is this for?
Show terms as
1Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Reticulate acropigmentation of Kitamura (RAK) is a rare inherited skin disorder characterized by a distinctive pattern of reticulate (net-like) hyperpigmented macules that primarily affect the dorsal surfaces of the hands and feet (acral areas). The condition was first described by the Japanese dermatologist Kitamura in 1943. It is also known as reticulate acropigmentation of Kitamura or Kitamura disease. The pigmented macules are typically small, slightly depressed, and arranged in a reticular pattern. Additional features may include pits or breaks in the epidermal ridges of the palms and soles (interrupted dermatoglyphics), which is considered a hallmark finding. Some patients may also develop pigmented macules on other body areas over time. The condition is caused by heterozygous loss-of-function mutations in the ADAM10 gene (a disintegrin and metalloproteinase domain 10), located on chromosome 15q21.3. ADAM10 plays a role in various cell signaling pathways, including Notch signaling, which is important for skin pigmentation and epidermal homeostasis. The onset of pigmentary changes typically begins in childhood, often in the first or second decade of life, and tends to progress slowly over time. The condition is generally benign and does not affect internal organs or overall health, though the cosmetic appearance can cause significant psychosocial distress. There is currently no curative treatment for reticulate acropigmentation of Kitamura. Management is primarily supportive and cosmetic. Sun protection is generally recommended to minimize further pigmentation. Topical depigmenting agents such as hydroquinone or retinoids have been tried with limited success. Laser therapies have been explored in some cases but results are variable and recurrence of pigmentation is common. Genetic counseling is recommended for affected individuals and their families given the autosomal dominant inheritance pattern.

Also known as:

Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Childhood

Begins in childhood, roughly ages 1 to 12

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

1 event
Mar 2025RAK-PRIDE: Optimizing Proton Pump Inhibitor Use Through Education and Intervention

RAK Medical and Health Sciences University — NA

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Reticulate acropigmentation of Kitamura.

View clinical trials →

No actively recruiting trials found for Reticulate acropigmentation of Kitamura at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Reticulate acropigmentation of Kitamura community →

Specialists

1 foundView all specialists →

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Reticulate acropigmentation of Kitamura.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Reticulate acropigmentation of KitamuraForum →

No community posts yet. Be the first to share your experience with Reticulate acropigmentation of Kitamura.

Start the conversation →

Latest news about Reticulate acropigmentation of Kitamura

Disease timeline:

New recruiting trial: Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3

A new clinical trial is recruiting patients for Reticulate acropigmentation of Kitamura

New recruiting trial: RAK-PRIDE: Optimizing Proton Pump Inhibitor Use Through Education and Intervention

A new clinical trial is recruiting patients for Reticulate acropigmentation of Kitamura

New recruiting trial: The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial

A new clinical trial is recruiting patients for Reticulate acropigmentation of Kitamura

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Reticulate acropigmentation of Kitamura

What is Reticulate acropigmentation of Kitamura?

Reticulate acropigmentation of Kitamura (RAK) is a rare inherited skin disorder characterized by a distinctive pattern of reticulate (net-like) hyperpigmented macules that primarily affect the dorsal surfaces of the hands and feet (acral areas). The condition was first described by the Japanese dermatologist Kitamura in 1943. It is also known as reticulate acropigmentation of Kitamura or Kitamura disease. The pigmented macules are typically small, slightly depressed, and arranged in a reticular pattern. Additional features may include pits or breaks in the epidermal ridges of the palms and sol

How is Reticulate acropigmentation of Kitamura inherited?

Reticulate acropigmentation of Kitamura follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Reticulate acropigmentation of Kitamura typically begin?

Typical onset of Reticulate acropigmentation of Kitamura is childhood. Age of onset can vary across affected individuals.

Which specialists treat Reticulate acropigmentation of Kitamura?

1 specialists and care centers treating Reticulate acropigmentation of Kitamura are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.